Literature DB >> 10102970

Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

N J Simmonds1, A D Millar, D R Blake, D S Rampton.   

Abstract

BACKGROUND: The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM: To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsalazide) and other potential therapies (ascorbate, N-acetylcysteine, glutathione, verapamil).
METHODS: Compounds were assessed for efficacy in reducing the in vitro production of reactive oxygen species by cell-free systems (using xanthine/xanthine oxidase, with or without myeloperoxidase) and by colorectal biopsies from patients with ulcerative colitis using luminol-amplified chemiluminescence.
RESULTS: 5-aminosalicylic acid and balsalazide were more potent antioxidants than 4-aminosalicylic acid or N-acetyl-5-aminosalicylic acid in cell-free systems. 5-aminosalicylic acid (20 mM) and balsalazide (20 mM) inhibited rectal biopsy chemiluminescence by 93% and 100%, respectively, compared with only 59% inhibition by 4-aminosalicylic acid (20 mM). Hydrocortisone, metronidazole and verapamil had no significant effect on chemiluminescence in any system. Ascorbate (20 mM) inhibited chemiluminescence by 100% in cell-free systems and by 60% in rectal biopsies. N-acetyl cysteine (10 mM), and both oxidized and reduced glutathione (10 mM), completely inhibited chemiluminescence in cell-free systems, but not with rectal biopsies.
CONCLUSIONS: The antioxidant effects of compounds varies between cell-free systems and inflamed colorectal biopsies. The effect of drugs on the chemiluminescence produced by these two assay systems is useful for screening potentially new antioxidant treatments for inflammatory bowel disease. Ascorbate seems worth further study as a novel therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102970     DOI: 10.1046/j.1365-2036.1999.00484.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

Review 2.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

3.  Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.

Authors:  Andrea L Matthis; Bin Zhang; Lee A Denson; Bruce R Yacyshyn; Eitaro Aihara; Marshall H Montrose
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

Review 4.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis.

Authors:  Sigrun Thorsteinsdottir; Thorkell Gudjonsson; Ole Haagen Nielsen; Ben Vainer; Jakob Benedict Seidelin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

6.  Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine.

Authors:  Yasotha Duraisamy; John Gaffney; Mark Slevin; Christopher A Smith; Kenneth Williamson; Nessar Ahmed
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

7.  The effects of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis in ovariectomized rats.

Authors:  Rauf Onur Ek; Mukadder Serter; Kemal Ergin; Yuksel Yildiz; Serpil Cecen; Tulay Kavak; Cigdem Yenisey
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

Review 8.  Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.

Authors:  Richard B R Muijsers; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

10.  In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.

Authors:  A Goel; A Mittal; R Evstatiev; M Nemeth; W Kruis; M Stolte; C R Boland; C Gasche
Journal:  Aliment Pharmacol Ther       Date:  2009-06-25       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.